Pharma Update

Oncology - solid tumor pipeline A leading portfolio differentiated on targets and modalities Ph I (26 NMEs) Ph II Ph III Launched RG6156 EGFRvIII x CD3 RG6185 RG6189 RG6194 belvarafenib (pan-RAF inh) FAP-CD40 RG6058 tiragolumab Multiple indications RG6058 tiragolumab Multiple indications Alecensa RG6058 1L ALK+ NSCLC runimotamab (HER2 x CD3) RG6279 eciskafusp alfa (PD1-IL2v) RG6139 tobemstomig Solid tumors RG6114 inavolisib HR+MBC RG3502 Kadcyla HER2+ BC RG6286 undislcosed RG6292 CD25 MAb RG6323 IL15/IL15Ra-Fc RG6180 autogene cevumeran 1L melanoma RG6171 giredestrant HR+ BC RG1273 Perjeta HER2+ BC mRNA RG6344 BRAF inhibitor (3) RG6353 HLA-G x CD3 RG6411 undisclosed divarasib RG7440 2L NSCLC RG6264 Phesgo HER2+ BC RG6433 SHP2i RG6440 TGFB (SOF10) RG6524 DLL3 trispecific RG65261 camonsertib RG6537 AR Degrader RG65962 ZN-1041 (HER2 TKI) RG66143 KSQ-4279 (USP1 inh) RG7802 cibisatamab mRNA RG7827 FAP-4-1BBL CHU glypican-3 x CD3 CHU codrituzumab CHU CD137 switch antibody CHU RAS inhibitor Small molecule Kadcyla RG3502 RG7446 HER2+ eBC high risk Antibody RG7446 Bispecifics/Trispecifics Tecentriq Multiple indications Neoantigen vaccines Alecensa RG6058 ALK+ NSCLC adj Fusion protein Antibody drug conjugate Cyclic peptides RG6268 Tecentriq Multiple indications Rozyltrek ROS1+ & NTRK+ NSCLC CHU SPYK04 CHU SAIL66 NME=new molecular entities; 'managed by Repare Therapeutics; 2managed by Zion Pharma; ³managed by KSQ Therapeutics Roche 70

View entire presentation